This is important news. Most don't realize that Doxil (doxorubicin hydrochloride) was the 4th drug approved by the FDA for use in multiple myeloma patients back in 2006. Kyprolis (carfilzomib) was the next myeloma drug approved over six years later last July. Doxil doesn't get a lot of love, partly because it is strictly an
Dr. Berenson dropped several bombshell this evening on our Myeloma Cure Panel discussion. REAL NEWS! Although Dr. Berenson couldn’t share specific date that he will be presenting next week at ASH in Atlanta, he let slip that substituting Kyprolis for Velcade in RVD or other multiple drug resistant patients is achieving surprisingly high success rates.
This is the type of thing that I usually post on MyelomaNews.com. But I wanted to get the news out as soon as possible. It looks like there may be an alternative to Doxil while the company which manufactures it tries to get it's act together: USA TODAY - Replacement found for cancer drug Doxil,
The Wall Street Journal's Peter Loftus reports that: "Johnson & Johnson doesn't expect to receive new supplies of its cancer drug Doxil from a troubled contract manufacturer's plant until late 2012, at the earliest. J&J will pursue other options to bring Doxil back to patients, including shifting production to another supplier, spokeswoman Lisa Vaga said
I know, I know. I'm falling behind! I'm so busy collecting and analyzing newly released myeloma related research data, I have barely had time to write. Here is the final installment of my three part report about the IMF's Friday evening Satellite Symposium. I saved the best for last! Dr. Robert Orlowski with M.D. Anderson
Friday I wrote an article about the worsening shortage of the myeloma drug, Doxil. This past weekend, the L.A. Times ran a feature story about Doxil and other chemotherapy drugs in short supply: Cancer drug Doxil joins growing list of drugs in short supply About 200 medications are on the FDA's drug shortage page. Sometimes
Last month I learned that my docs could not add Doxil to my RVD (Revlimid/Velcade/dexamethasone) consolidation treatment regimen. Doxil is the drug Doxorubicin encapsulated in a closed lipid sphere. Seems Doxil is part of the much publicized chemotherapy drug shortage. While this probably isn't a life or death thing for me, I hate to see
Yesterday I shared impressive, in-depth therapy analysis of my case by Dr. Robert Orlowski, at M.D. Anderson in Houston, Texas. Today, let's hear what Dr. James Berenson, founder of the Institute for Myeloma and Bone Cancer Research in Los Angeles, has to say. I interviewed Dr. Berenson in his offices just outside of Beverly Hills
Carfilzomib, Elotuzumab, Panobinostat, Vorinostat And Arry520 All Show Promise In Late Stage Clinical Studies Against Multiple Myeloma
Yesterday I wrote about three anti-myeloma clinical studies involving carfilzomib, elotuzumab and panobinostat. I referred to elotuzumab and panobinostat as promising "assisting type" drugs. Also known as secondary or “helper” novel therapy agents, elotuzumab, panobinostat, vorinostat and/or ARRY520 are all showing promise working with primary novel therapy agents like thalidomide, Revlimid and Velcade. It is
Let's jump right in with more ASCO news. Of course, there were lots of study results featuring new drugs used in combination with Revlimid and Velcade. As you should have noticed by now, the combination approach is the new "in thing" when treating myeloma. The Revlimid/Velcade/dexamethasone (RVD) induction combination I'm enduring now, prior to my stem
I have received a number of calls and e-mails recently from patients who's multiple myeloma has become active again while using Revlimid, Velcade, or both. Here is a short, hopeful response I found addressing this on the Multiple Myeloma Research Foundation (MMRF) Website:Treatment Options for Relapsed or Refractory Patients Failing Revlimid and Velcade: Q&A with
Exciting New Multiple Myeloma Therapy Study Overview Published In Blood: Union Of Forces Advances Myeloma Care
While attending an International Myeloma Foundation (IMF) Patient and Family Seminar last fall in Minneapolis, I met an impressive, young myeloma doc and researcher on the rise, Mayo Clinic's Dr. Kieth Stewart. I felt he had a very reasonable and balanced approach to myeloma therapy. Here is a research paper the prestigious hematological publication, Blood,
Here are a number of multiple myeloma related news stories which have emerged over the past few days:Posted on 05/05/2010 in Pharmaceutical Company Product News Boehringer Ingelheim is to enter into partnership with cancer antibody specialist Micromet in order to develop a new treatment for multiple myeloma.The two firms' collaboration will be centred on a BiTE
The 4:30 presentation titled "Therapy Excluding Transplantation: Combination Therapy For Newly Diagnosed Multiple Myeloma," was, in a way, more of the same. Very similar data to other presentations I saw today, with a few key differences. In elderly patients, it turns out the Italians treat their patients in a way similar to those in Spain.
Program Director Dr. Brian Durie has just introduced tonight's panel: Dr. Mario Boccadoro from Italy, Dr. Philippe Moreau from France, Dr. Robert Orlowski with M.D. Anderson Cancer Centers and Dr. Vincent Rajkumar from Mayo Clinic. 400+ docs, researchers, drug reps, oncology nurses and a few of us patients, fill the room. The presentations have begun.
Dexamethasone has been combined with novel chemotherapy drugs like Thalomid, Velcade and Revlimid for years. But now there are a few newer drugs which are also starting to be used in combination as well. Doxil, cyclophosphamide and vorinostat are examples of this. All three are either available now, or have recently completed successful Phase III
More about the patient conference at Millennium tomorrow. I received this e-mail from Debbie Stanley yesterday and, with her permission, wanted to share it with my readers:My husband had tandem transplants in April 2005 and September 2005. They didn't put him in remission so he started Velcade treatments. He had to stop after 3 treatments